Down-regulation of vinculin upon MK886-induced apoptosis in LN18 glioblastoma cells

Neoplasma

Volumn 54, Issue 6, 2007, Pages 517-526

  Magro, A M ^a   Magro, A D ^a   Cunningham, C ^b   Miller, M R ^b  

^a FAIRMONT STATE UNIVERSITY   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

5 lipoxygenase; Apoptosis; FLAP; Glioblastoma; MK886; PPAR

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ACTIN; ARACHIDONATE 12 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE ACTIVATING PROTEIN; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; VINCULIN; 5-LIPOXYGENASE-ACTIVATING PROTEIN; CARRIER PROTEIN; INDOLE DERIVATIVE; LIPOXYGENASE INHIBITOR; MEMBRANE PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GLIOBLASTOMA; HUMAN; HUMAN CELL; BIOSYNTHESIS; DRUG EFFECT; METABOLISM; MITOCHONDRION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ACTINS; APOPTOSIS; CARRIER PROTEINS; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; INDOLES; LIPOXYGENASE INHIBITORS; MEMBRANE PROTEINS; MICROSCOPY, FLUORESCENCE; MITOCHONDRIA; PPAR ALPHA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; VINCULIN;

EID: 38949198823     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (53)

1. YUNG WK, ALBRIGHT RE, OLSON J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000; 83: 588-593. (Pubitemid 30636298)
2. STUPP R, MASON WP, van den BENT MJ, et al. The European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups and the National Cancer Institute of Canada Clinical Trials Group Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. New England J of Med 2005; 352:987-996. (Clinical Study, Abstract)
3. HEGI ME, DISERENS AC, GORLIA T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. New England J Med 2005; 352: 997-1003.
4. DIXON RAF, DIEHL RE, OPAS E, et al. Requirement of a 5-lipoxygenase- activating protein for leukotriene synthesis. Nature 1990; 343: 282-284. (Pubitemid 20030648)
5. MILLER DK, GILLARD JW, VICKERS PJ, et al. Identification and isolation of a membrane protein necessary for leukotriene production. Nature 1990; 343: 278-281. (Pubitemid 20030647)
6. FORD-HUTCHINSON AW. FLAP: A novel drug target for inhibiting the synthesis of leukotrienes. Trends Pharmacol Sci 1991; 12: 68-70.
7. ANDERSON KM, SEED T, JAJEH A, et al. An in vivo inhibitor of 5-lipoxygenase, MK886, at micormolar concentration induces apoptosis in U937 and CML cells. Anticancer Res 1996; 16(5A): 2589-2599.
8. GHOSH J and MYERS CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci USA 1998; 95: 13182-13187.
9. GHOSH J and MYERS CE. Arachidonic acid stimulates prostate cancer cell growth: Critical role of 5-lipoxygenase. Biochem Biophys Res Commun 1997; 235(2): 418-423(6).
10. TONG WG, DING XZ, ADRIAN TE. The mechanisms of lipoxygenase inhibitor- induced apoptosis in human breast cancer cells. Biochem Biophys Res Commun 2002; 296: 942-948.
11. DING XZ, TONG WG, ADRIAN TE. Cyclooxygenases and lipoxygenase potential targets for treatment of pancreatic cancer. Pancreatology 2001; 1: 91-99.
12. ROMANO M AND CLARIA J. Cyclooxygense-2 and 5-lipoxygenase converging function on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003; 17: 1986-1995.
13. DATTA K, BISWAL SS, KEHRER JP. The 5-lipoxygenase-activating protein (FLAP) inhibitor, MK886, induces apoptosis independently of FLAP. Biochem J 1999; 340: 371-375.
14. YU K, BAYANO W, KALLEN CB, et al. Diverential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995; 270: 23975-23983.
15. DEVCHAND PR, KELLER H, PETERS JM, et al. The PPARα-leukotriene B4 pathway to inflammation control. Nature 1996; 384: 39-43.
16. FORMAN BM, CHEN J, EVANS RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci USA 1997; 94: 4318-4323.
17. KLIEWER SA, SUNDSETH SS, JONES SA, et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 1997; 94: 4312-4317.
18. KEHRER JP, BISWAL SS, THUILLIER P, et al. Inhibition of peroxisome proliferator- activated receptor alpha (PPARα) by MK886. Biochem J 2001; 356: 899-906. (Pubitemid 32588464)
19. DISERENS AC, DE TRIBOLET N, MARTIN-ACHARD A, et al. Characterization of an established human malignant glioma cell line: LN-18. Acta Neuorpathol 1981; 53: 21-28. (Pubitemid 11178990)
20. HACKER G. The morphology of apoptosis. Cell Tissue Res 2000; 301: 5-17.
21. McCARTY MF. Targeting multiple signaling pathways as a strategy for managing prostate cancer: multifocal signal modulation therapy. Integrative Cancer Therapies 2004; 3: 349-380.
22. ISHII N, MAIER D, MERLO A, et al. Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol 1999; 9: 469-479.
23. SCHLAPBACH R AND FONTANA A. Differential activity of bcl-2 and ICE enzyme family protease inhibitors on FAS and puromycin-induced apoptosis of glioma cells. Biochim Biophys Acta 1997; 1359: 174-180.
24. GUGLIUCCI A, RANZATO L, SCORRANO L, et al. Mitochondria are direct targets of the lipoxygenase inhibitor MK886. A strategy for cell killing by combined treatment with MK886 and cyclooxyenase inhibitors. J Biol Chem 2002; 277(35): 31789-31795.
25. LUGLI E, TROIANO L, FERRARESI R, et al. Characterization of cells with different mitochondrial membrane potential during apoptosis. Cytometry Part A 2005; 28-35. (Pubitemid 41572060)
26. DIN XZ, KUSZYNSKI CA, EL-METWALLY TH, et al. Lipoxygenase inhibition induced apoptosis, morphological changes, and carbonic anhydrase expression in human pancreatic cancer cells. Biochem Biophys Res Commun 1999; 392-399.
27. GHOSH J and MYERS CE. Central role of arachidonate 5-lipoxygenase in the regulation of cell growth and apoptosis in human prostate cancer cells. Adv Exp Med Biol 1999; 469: 577-582.
28. STEELE VE, HOLMES CA, HAWK ET, et al. Lipoxygenase inhibitors as potential cancer chemopreventives. Canc Epidemiol Biomarkers Prev 1999; 8: 467-483. (Pubitemid 29230553)
29. SHUREIQI I AND LIPPMAN SM. Lipoxygenase modulation to reverse carcinogensis. Cancer Res 2001; 61: 6307-6312.
30. LEMBERGER T, DESVERGNE B, WAHLI W. PPARs: a nuclear receptor signaling pathway in lipid metabolism. Annu Rev Cell Dev Biol 1996; 12: 335-363.
31. ROBERTS RA, JAMES NH, WODDYATT NJ, et al. Evidence for the suppression of apoptosis by the peroxisome proliferator activated receptor alpha (PPARα). Carcinogensis 1998; 19: 43-48.
32. MICHALIK L, DESVERGNE B, WAHLI W. Peroxisome-proliferator-activated receptors and cancers: complex stories. Nat Rev Cancer 2004; 4: 61-70.
33. NAAGOTHU KK, BHATT R, KAUSHAL GP, PORTILLA D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68(6): 2680-2693.
34. MULSHINE JL and JETT M. Use of lipoxygenase inhibitors and PPAR ligands as anti-cancer therapeutic and intervention agents. US Patent 2004; #6, 756, 399.
35. MAYBURD AL, MARTINEZ A, SACKETT D, et al. Ingenuity network-assisted transcription profiling: Identification of a new pharmacologic mechanism for MK886. Clinic Canc Res 2006; 12(6): 1820-1827.
36. BURRIDGE K and MANGEAT P. An interaction between vinculin and talin. Nature 1984; 308: 744-746.
37. BELKIN AM and KOTELIANSKY VE. Interaction of iodinated vinculin, metavinculin, and alpha-actinin with cytoskeletal protein. FEBS Lett 1987; 220: 291-294.
38. RUHNAU K and WEGNER A. Evidence for direct binding of vinculin to actin filaments. FEBS 1988; 228: 105-108. (Pubitemid 18039478)
39. TURNER CE, GLENNEY JR Jr., BURRIDGE K. Paxillin: a new vinculin-binding protein present in focal adhesions. J Cell Biol 1990; 111: 1059-1068. (Pubitemid 20263787)
40. RUOSLAHTI E AND OBRINK B. Common principles in cell adhesion. Exp Cell Res 1996; 227: 1-11.
41. RAZ A and GEIGER B. Altered organization of cell-substrate contacts and membrane-associated cytoskeleton in tumor cell variants exhibiting different metastatic capabilities. Cancer Res 1982; 42: 5183-5190.
42. HOWE AK, ALPIN AE, JULIANO RL. Anchorage-dependent ERK signaling mechanisms and consequences. Curr Opin Genet Dev 2002; 12: 30-35.
43. SUBAUSTE MC, PERTZ O, ADAMSON ED, et al. Vinculin modulation of paxillin-FAK interactions regulates ERK to control survival and motility. J Cell Biol 2004; 165(3): 371-381.
44. COLL JL, BEN-ZE'EV A, EZZELL RM, et al. Targeted disruption of vinculin gene in F9 and ES cells changes cell morphology, adhesion, and locomotion. Proc Nat Acad Sci USA 1995; 92: 9161-9165.
45. ZIEGLER WH, LIDDINGTON RC, CRITCHLEY DR. The structure and regulation of vinculin. Trends in Cell Biol 2006; 16: 453-460.
46. CHEN H, COHEN DM, CHOUDHURY DM, et al. Spatial distribution and functional significance of activated vinculin in living cells. J Cell Biol 2005; 169: 459-470. (Pubitemid 40686696)
47. FRISCH SM AND FRANCIS H. Disruption of epithelial cell-matrix interactions induces apoptosis. J Cell Biol 1994; 124: 619-626.
48. FRISCH SM and RUOSLAHTI E. Integrins and anoikis. Curr Opin Cell Biol 1997; 9: 701-706.
49. FRISCH SM, VUORI K, RUOSLAHTI E, CHAN-HUI PY. Control of adhesion-dependent cell survival by focal adhesion kinase. J Cell Biol 1996; 134: 793-799.
50. DOWNWARD J. Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998' 10: 262-267. (Pubitemid 28174769)
51. GIULIAN D, CORPUZ M, CHAPMAN S, et al. Reactive mononuclear phagocytes release neurotoxins after ischemic and traumatic injury to the central nervous system. J Neurosci Res 1993; 36: 681-693.
52. McGREER PL, KAWAMATA T, WALKER DG, et al. Microglia in degenerative neurological disease. Glia 1993; 7: 84-92.
53. KREUTZBERG GW. Microglia, the first line of defense in brain pathologies. Arzneimittelforschung 1995; 45: 357-360.